TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03846973
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous infusion of 1 g infusion to be given and completed over 8 h in the hospital
Study: NCT00003882
Drug: anhydrovinblastine
Normalized name: Anhydrovinblastine
DrugBank: Anhydrovinblastine (DB12586)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02216890
Drug: SGN-CD70A
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously every 3 weeks (or an alternate dosing schedule up to every 6 weeks)
Study: NCT02251158
Drug: Tipranavir oral solution
Normalized name: tipranavir Oral Solution
DrugBank: Tipranavir (DB00932)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02251158
Drug: Tipranavir capsules
Normalized name: tipranavir Oral Capsule
DrugBank: Tipranavir (DB00932)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02251158
Drug: Ritonavir oral solution
Normalized name: Ritonavir Oral Solution
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02251158
Drug: Ritonavir soft gel capsules
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03179410
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg/kg intravenously every 2 weeks
Study: NCT00719537
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81 mg once a day
Study: NCT00719537
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Progesterone 200 mg Twice Daily
Study: NCT00158405
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00158405
Drug: Lamivudine (3TC)
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00158405
Drug: Efavirenz (EFV)
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00158405
Drug: Ritonavir (NRV)
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00158405
Drug: Indinavir (IDV)
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00045630
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00045630
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00045630
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04737980
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of 10 ml of liposomal bupivacaine 1.3% (133 mg) for ultrasound guided interscalene block
Study: NCT04737980
Drug: Bupivacaine Hcl 0.5% Inj
Normalized name: BUPIVACAINE HCL 0.5% INJ
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of 10 ml of 0.5% bupivacaine hydrochloride as admixture for ultrasound guided interscalene block
Study: NCT04737980
Drug: Ropivacaine 0.5% Injectable Solution
Normalized name: ROPivacaine 0.5% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of 30 ml of ropivacaine 0.5% injectable solution for ultrasound guided interscalene block
Study: NCT04737980
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injection of 8mg (2ml) dexamethasone injectable as admixture
Study: NCT01557504
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Concomitant use of metformin is permitted during the study provided the participant has been receiving a stable metformin dose for at least 12 weeks prior to the dose of study drug. Administration of metformin will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
Study: NCT02381548
Drug: Adavosertib
Normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02381548
Drug: Belinostat
Normalized name: Belinostat
DrugBank: Belinostat (DB05015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03108625
Drug: Vortioxetine
Normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Target dose is 10 mg/day; the dose can be down- or uptitrated to 5, 15, or 20 mg/day.
Study: NCT01003613
Drug: Tranilast, and Tissucol
DrugBank: Tranilast (DB07615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0%, 0.1 ml, subconjunctival route, single dose
Study: NCT01557504
Drug: Thyroid hormone
Normalized name: Thyroid hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant use of thyroid hormone (eg, levothyroxine) is permitted during the study provided the participant has been receiving a stable dose for at least 12 weeks prior to study drug administration and is euthyroid as documented by thyroid stimulating hormone testing at prestudy. Administration of thyroid hormone will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
Study: NCT02020291
Drug: Foxy-5
Normalized name: Foxy-5
DrugBank: Foxy-5 (DB13034)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03063788
Drug: 3BNC117-Copper-64
Normalized name: COPPER CU-64
DrugBank: Copper (DB09130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg 3BNC117 combined with radio-isotope Copper-64
Study: NCT02174419
Drug: nalbuphine HCl ER tablets 90 mg BID
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nalbuphine HCl ER tablets 90 mg BID administered for 8 weeks
Study: NCT00631618
Drug: Sutent (sunitinib)
Normalized name: sunitinib Oral Capsule [Sutent]
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The initial dose will be 50mg daily taken for 4 consecutive weeks followed by 2-weeks off to comprise a complete cycle of 6 weeks.
Study: NCT03375138
Drug: belatacept
Normalized name: Belatacept
DrugBank: Belatacept (DB06681)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT02174419
Drug: nalbuphine HCl ER tablets 180 mg BID
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nalbuphine HCl ER tablets 180 mg BID administered for 8 weeks
Study: NCT01034202
Drug: NNC126-0083
Normalized name: NNC126-0083
DrugBank: Somatropin pegol (DB15112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One of five dose levels administered subcutaneously (under the skin)
Study: NCT01034202
Drug: NNC126-0083
Normalized name: NNC126-0083
DrugBank: Somatropin pegol (DB15112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One of three dose levels administered subcutaneously (under the skin)
Study: NCT03010267
Drug: DP-R213
Normalized name: DP-303c
DrugBank: DP-303c (DB17212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational product is prescribed to all of randomized subjects
Study: NCT03010267
Drug: Raloxifene
Normalized name: Raloxifene
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Investigational product is prescribed to all of randomized subjects
Study: NCT03540914
Drug: ACETAZOLAMIDE oral capsule
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
Study: NCT01670812
Drug: FFP+HDMP+Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This is a single arm, multicenter clinical trial, and the regimen including Fresh frozen plasma 400ml IV day0, Rituximab: 375 mg/m2 IV day0(after infusion of FFP), methylprednisolone 1g/m2(up to 1.5g) IV day1-day5
Study: NCT00883506
Drug: Lisinopril 40 mg Tablet (Zestril) under fed conditions.
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00883506
Drug: Lisinopril 40 mg Tablet under fasting conditions.
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04344262
Drug: Atracurium Besylate regular dose
Normalized name: Atracurium Besylate
DrugBank: Atracurium besylate (DB00732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intubating dose of muscle relaxant will be atracurium 0.5 mg/kg~Maintenance doses of muscle relaxant will be given throughout the intraoperative period~to maintain the Train-of-four values continuously less than 2
Study: NCT04344262
Drug: Atracurium Besylate minial dose
Normalized name: Atracurium Besylate
DrugBank: Atracurium besylate (DB00732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: atracurium boluses of muscle relaxant given only upon complain of the surgeon and after a bolus dose of propofol 0.5 mg/kg. When required, 20% of the initial dose of muscle relaxant will be provided as a bolus to achieve this goal
Study: NCT00251589
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat 200 mg twice a day for 3 days a week.
Study: NCT00251589
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat 300 mg once a day for 3 days a week.
Study: NCT00251589
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat 300 mg twice a day for 3 days a week.
Study: NCT00251589
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat 400 mg once a day for 21 out of 28 days.
Study: NCT00251589
Drug: erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: erlotinib 150 mg once a day.
Study: NCT02863705
Drug: bimatoprost ophthalmic solution 0.01%
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost ophthalmic solution 0.01% (LUMIGAN®) administered once daily in the evening 5 minutes after COMBIGAN® instillation if additional lowering IOP is needed
Study: NCT00251277
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab will be administered immediately after pheresis to minimize the amount of Rituximab that is removed by the subsequent days pheresis. The guidelines will be that 12 hours must elapse between the end of the first infusion of study drug and the next pheresis. Subsequent infusions would be weekly (plus or minus 2 days) with an attempt made to give study drug infusions after a pheresis that might be the last in a series, i.e. when no pheresis would be scheduled for at least the next day.
Study: NCT00883506
Drug: Lisinopril 40 mg Tablet under fed conditions.
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02979366
Drug: S64315 once a week
Normalized name: risedronate
DrugBank: S64315 (DB17559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S64315 will be administered via i.v. infusion from 30 minutes and up to 3 hours once every week (21- day cycle), the starting dose is 50 mg. As data emerge during the study, the infusion duration and alternative dosing regimen may be changed.
Study: NCT02979366
Drug: S64315 twice a week
Normalized name: Tice BCG
DrugBank: S64315 (DB17559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S64315 will be administered via i.v. infusion from 30 minutes and up to 3 hours twice every week (28- day cycle), the starting dose is 50 mg. As data emerge during the study, the infusion duration and alternative dosing regimen may be changed.
Study: NCT00953225
Drug: vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4,000 IU daily for one year
Study: NCT01635608
Drug: Talinolol
Normalized name: talinolol
DrugBank: Talinolol (DB11770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of 50 mg talinolol
Study: NCT01635608
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administration of 500 mg amoxicillin
Study: NCT01090102
Drug: Mesalamine (5-aminosalicylic acid, Apriso)
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Four mesalamine capsules once daily (1.5 gram/day) for the first 12 weeks, PO(by mouth).~Four placebo capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth).
Study: NCT02708992
Drug: Cefixime
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02451488
Drug: GM-CSF
Normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 days in a dose of 125 µg/m\^2
Study: NCT04062370
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive intravitreal injection of Ranibizumab 0.5 mg (1+PRN or 3+PRN) according to the study until month 6. Then, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN after month 6.
Study: NCT01216345
Drug: Cetuximab + Gemcitabine + Oxaliplatin
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 500mg/m2, iv every two weeks Gemcitabine 1000mg/m2, iv every two weeks Oxaliplatin 100mg/m2, iv every two weeks
Study: NCT01628393
Drug: Ozanimod
Normalized name: Ozanimod
DrugBank: Ozanimod (DB12612)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral capsule taken once a day
Study: NCT00493610
Drug: N-acetylcysteine(Mucomyst)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02323399
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one of six initial treatments Phenylephrine Hydrochloride Injection (PHI) will be initially administered to approximately 50 subjects as an intravenous bolus (IV-B) at Low (1 μg/kg), Med (3 μg/kg), or High (5 μg/kg) level; PHI will be initially administered to approximately 50 subjects as a continuous intravenous infusion (IV-I) at Low (0.25 μg/kg/min), Med (0.75 μg/kg/min), or High (1.25 μg/kg/min) level\]; each initial treatment group will have two PK sampling schedules.
Study: NCT03257618
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment with TMZ will be given orally according to standard practices. The therapeutic schedule will be left at the investigator's discretion.~Patients will be followed every 3 months during the treatment period, at the end of the treatment with TMZ, 6 months after the end of TMZ, and then annually until tumor progression.
Study: NCT00352066
Drug: apricitabine
Normalized name: Apricitabine
DrugBank: Apricitabine (DB12855)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03067844
Drug: Alirocumab
Normalized name: Alirocumab
DrugBank: Alirocumab (DB09302)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pre-filled auto-injector pen every second week, starting at day 1 and up to week 50
Study: NCT00563368
Drug: VI-0521
Normalized name: VIS-410
DrugBank: VIS-410 (DB19067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: phentermine 15 mg and topiramate 92 mg, po once daily
Study: NCT00563368
Drug: VI-0521
Normalized name: VIS-410
DrugBank: VIS-410 (DB19067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: phentermine 7.5 mg and topiramate 46 mg, po once daily
Study: NCT00563368
Drug: topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: topiramate 46 mg, po once daily
Study: NCT00563368
Drug: topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: topiramate 92 mg, po once daily
Study: NCT00563368
Drug: phentermine
Normalized name: Phentermine
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: phentermine 7.5 mg, po once daily
Study: NCT00563368
Drug: phentermine
Normalized name: Phentermine
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: phentermine 15 mg, po once daily
Study: NCT00563368
Drug: VI-0521
Normalized name: VIS-410
DrugBank: VIS-410 (DB19067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, po once daily
Study: NCT01629628
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous adalimumab injections, loading dose of 160 mg and 80 mg on 0 and 2 weeks and maintenance of 40 mg every other week for the duration of the study.
Study: NCT03347617
Drug: Ferumoxytol
Normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT02366689
Drug: Triclosan/fluoride toothpaste
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brush whole mouth with Total toothpaste (triclosan/fluoride) using Total 360 toothbrush for 1 minute, 2 times/day for 6 months (study duration).
Study: NCT02366689
Drug: stannous fluoride toothpaste
Normalized name: stannous fluoride Toothpaste
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brush whole mouth with Crest Pro-Health toothpaste using an Oral B Pro-Health toothbrush for 1 minute, 2 times/day for 6 months (study duration).
Study: NCT02366689
Drug: fluoride only toothpaste
Normalized name: sodium fluoride Toothpaste [Fluoridex]
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brush whole mouth with Crest Cavity Protection toothpaste using an Oral B Indicator toothbrush for 1 minute, 2 times/day for 6 months (study duration). Immediately after each brushing, rinse whole mouth with 20 ml of Crest fluoride Mouthwash for 30 seconds.
Study: NCT02366689
Drug: Cetylpyridinium chloride mouthwash
Normalized name: cetylpyridinium chloride Mouthwash
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediately after each brushing with Crest Pro-Health toothpaste, rinse whole mouth with 20 ml of Crest Pro-Health Mouthwash for 30 seconds.
Study: NCT02366689
Drug: Fluoride only mouthwash
Normalized name: sodium fluoride Mouthwash
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediately after each brushing with Crest Cavity Protection toothpaste, rinse whole mouth with 20 ml of Crest Pro-Health For Me mouthwash for 30 seconds.
Study: NCT02773550
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Low dose of bortezomib
Study: NCT02773550
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02773550
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01345630
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc tablet 150 mg once daily for 96 weeks.
Study: NCT01345630
Drug: Emtricitabine/tenofovir
Normalized name: EMTRICITABINE/TENOFOVIR
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Emtricitabine/tenofovir tablet 200/300 mg once daily for 96 weeks.
Study: NCT01345630
Drug: darunavir/ritonavir 800/100 mg
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: darunavir/ritonavir 800/100 mg
Study: NCT01345630
Drug: placebo for emtricitabine/tenofovir
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: placebo for emtricitabine/tenofovir
Study: NCT01345630
Drug: placebo for maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: placebo for maraviroc
Study: NCT01287598
Drug: Regorafenib (Stivarga, BAY73-4506)
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BAY73-4506 administered once a daily (od) in a 21-day on / 7-day off schedule
Study: NCT01287598
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CYP 2C9 (warfarin) at Cycle 1
Study: NCT01287598
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CYP 2C19 (omeprazole) at Cycle 1
Study: NCT01287598
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CYP 3A4 (midazolam) at Cycle 1
Study: NCT01287598
Drug: Rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CYP2C8 (rosiglitazone) at Cycle 1
Study: NCT02721342
Drug: Ramipril, Irbesartan and Atorvastin
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02492373
Drug: topical 0.05% Clobetasol propionate ointment
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Apply only on the treated area twice a day as mentions
Study: NCT03588091
Drug: Pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pyrotinib: 400mg orally daily;
Study: NCT03588091
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 4 cycles;
Study: NCT03588091
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel:after the biological window, 100mg/m2 for a total of 4 cycles
Study: NCT01062425
Drug: Cediranib Maleate
Normalized name: maleate
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01062425
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03347110
Drug: Bimekizumab
Normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Bimekizumab at a prespecified dose.
Study: NCT02038010
Drug: PI3K inhibitor BYL719
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02543658
Drug: Neostigmine Methylsulfate 1 MG/ML
Normalized name: neostigmine methylsulfate 1 MG/ML
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The initial dose was 1mg, intramuscular injection(IM) once every 12 hours. If there is no defecation after 12 hours, the dose is increased to 1mg IM once every 8 hours; if there is no defecation after 24 hours, the dose is increased to 1mg IM once every 6 hours. If the abdominal pressure drops below 12mmhg, neostigmine will be stopped, otherwise it will be used continuously for 7 days.
Study: NCT02294994
Drug: tirofiban
Normalized name: Tirofiban
DrugBank: Tirofiban (DB00775)
Approvals — FDA: yes, EMA: no, PMDA: no